First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonopraza ...

财务业绩 - 公司第三季度每股亏损0.15美元 显著优于市场预期的每股亏损0.3美元 较去年同期的每股亏损1.32美元大幅收窄[1] - 本季度营收为4950万美元 略超市场预期0.64% 较去年同期的1635万美元大幅增长[2] - 在过去四个季度中 公司两次超过每股收益预期 四次超过营收预期[2] 市场表现与预期 - 公司股价年初至今上涨约66.6% 显著跑赢同期标普500指数17.2%的涨幅[3] - 当前市场对下一季度的共识预期为每股亏损0.17美元 营收5535万美元 对本财年的共识预期为每股亏损2.31美元 营收1.7256亿美元[7] - 公司目前的Zacks评级为3级（持有）预计近期表现将与市场同步[6] 行业比较 - 公司所属的医疗-生物医学和遗传学行业在Zacks行业排名中位列前38%[8] - 同业公司VistaGen Therapeutics预计在下一份报告中公布季度每股亏损0.51美元 较去年同期恶化21.4% 但其每股收益预期在过去30天内被上调了11.1%[9] - VistaGen Therapeutics预计季度营收为63万美元 较去年同期增长250%[9]

Phathom Pharmaceuticals (NasdaqGS:PHAT) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Speaker0Hello and welcome to the Phathom Pharmaceuticals third quarter 2025 earnings results call. At this time, all participants are in a listen only mode. After the presentation, there will be a question and answer session. To raise your hand to ask a question, press Star 11. To lower your hand, you may press Star 11 again. Please be advised that today's call is being recorded. With that, I would like to turn the ca ...

THIRD QUARTER 2025 EARNINGS CONFERENCE CALL Question & Answer Steven Basta, President & Chief Executive Officer Sanjeev Narula, Chief Financial and Business Officer Robert Breedlove, Principal Accounting Officer OCTOBER 2025 NASDAQ: PHAT Today's Agenda Business Update Steven Basta, President & Chief Executive Officer Q3 2025 Financial Results Sanjeev Narula, Chief Financial and Business Officer Closing Remarks Steven Basta, President & Chief Executive Officer 2 Safe harbor This presentation contains forward ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to . Delaware 82-4151574 (State or other jurisdiction of incorporation or organization) 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 (Address of princi ...

Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update FLORHAM PARK, N.J., October 30, 2025 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "Our performance this quarter reinforces our belief in the strength of our GI-fo ...

Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) --  Phathom Pharmaceuticals, Inc. ( ...

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heartburn-free nights observed after the first dose and maintained through 24 weeks of treatmentAnalysis of exploratory endpoints showed durable improvements in measures of nocturnal symptom severity and sleep-related impacts throughout the full treatment period FLORHAM PARK, N ...

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology’s (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona. Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, in ...

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update. A live webcast and additional inform ...